First line treatment for chronic lymphocytic leukemia - Industry News

Enlai News

联系我们

Outbound sales&marketing

Contact：Mr. Yang
Tel：+86-28-84871826
Mobile：+86 13908183771
Email：sealinfa@enlaibio.com

Outbound sales&marketing

Contact：Manager Tang
Mobile：+86 18054780191
Email：Amy@enlaibio.com

Outbound sales&marketing

Contact：Manager Yi
Tel：+86-28-84841969
18980456393
Mobile：+86 18728045915
Email：nero@enlaibio.com

Outbound sales&marketing

Contact：Manager Jiang

Tel：+86-28-64841719

Mobile：+86 17390183901
Email：cynthia@enlaibio.com

Your current location:Homepage >

As a first line treatment drugs for chronic lymphocytic leukemia, Ibrutinib improves survival compared with Ofatumumab in patients with previously treated Chronic Lymphocytic Leukemia.As a first line treatment drugs for chronic lymphocytic leukemia, Ibrutinib improves survival compared with Ofatumumab in patients with previously treated Chronic Lymphocytic Leukemia.

The typical cost of ibrutinib in the United States is about $148,000 a year.

In China, Ibrutinib was added to the Chinese Pharmaceutical Benefits Scheme in 2018.

In the previous:None
The next article:From Poverty to Harvard Postdoc